Patient Perceptions and Quality of Life Associated With the Use of Olapatadine 0.2% for the Treatment of Allergic Conjunctivitis

The purpose of this study is to evaluate patient perceptions of olopatadine 0.2% dosed once daily in patients previously treated with twice-daily, topical, ocular, anti-allergy medications.

Inclusion Criteria:

• 12 years of age or older.
• History (within the past 24 months) of allergic conjunctivitis.
• Active signs and symptoms of ocular allergies.
• Ocular health within normal limits, as determined by the investigator or subinvestigator.
• Willing to avoid contact lens wear each study visit immediately prior to study medication instillation and for 10 minutes after instillation of study drug.
• Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

• Contraindications or hypersensitivity to study medication or its components.
• One sighted eye or not correctable to 0.6 logMAR or better in both eyes at the screening visit.
• Known history of recurrent corneal erosion syndrome.
• Ocular trauma or surgical intervention within 6 months prior to Visit 1.
• Participation in any other investigational study within 30 days before Visit 1.
• Pregnant or nursing.
• Other protocol-defined exclusion criteria may apply.